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The level of genomic amplification of the human telomerase gene TERC, which maps to chromosome band 3q26, was determined in
primary cervical adenocarcinomas. Interphase nuclei prepared from archival material of 12 primary cervical adenocarcinomas, eight of
which were human papillomavirus positive, were hybridised with a triple colour probe set specific for centromeres of chromosomes
3 and 7 and the TERC gene. We observed high proportions of nuclei with increased absolute copy numbers for TERC in all tumours
(mean 3.3; range 2.3–5.2). Amplification of the human telomerase gene TERC is a consistent aberration in cervical adenocarcinomas.
Therefore, application of our probe set may provide an objective genetic test for the assessment of glandular cells in Pap smears and
hence for the diagnosis of cervical adenocarcinomas.
British Journal of Cancer (2006) 95, 331–338. doi:10.1038/sj.bjc.6603253 www.bjcancer.com
Published online 18 July 2006
& 2006 Cancer Research UK
Keywords: cervical adenocarcinoma; human papillomavirus; interphase fluorescence in situ hybridisation; chromosome arm 3q;
telomerase; early detection
                                                
Cervical cancer is a disease that mainly affects women in the forth
or fifth decade of life. According to the International Agency for
Research on Cancer (IARC), it is the second most common cancer
in women worldwide, and in developing nations it is the most
common cancer in women (Parkin et al, 2001). Two main types of
cervical cancer are described, that is, squamous cell carcinoma and
adenocarcinoma. Cervical adenocarcinomas comprise 20% of all
cervical cancers that are diagnosed (Vizcaino et al, 1998).
Importantly, in the last few decades the incidence of cervical
adenocarcinoma among young women has been steadily increas-
ing (Vizcaino et al, 1998; Bergstro ¨m et al, 1999; Smith et al, 2000;
Sasieni and Adams, 2001); however, the reasons for this increase
are presently unknown. Applications of clinical screening pro-
grammes that have led to a decrease in squamous cell carcinoma
have only shown a limited effect on the occurrence of adenocarci-
nomas. This is owing to the fact that the sensitivity for detecting
precursor lesions of adenocarcinomas is much lower than for the
detection of precursor cells of squamous carcinomas. This can be
partly explained by the difficulty in the morphological assessment
of highly differentiated glandular cells, which can be derived from
adenocarcinomas of the endocervix. In addition to these
difficulties, the endocervix is less accessible for cytological
sampling (Bergstro ¨m et al, 1999).
Epidemiological and molecular biological studies have shown
that infection with high-risk human papillomavirus (HPV) is an
important aetiological agent in the pathogenesis of cervical
adenocarcinoma (Bosch et al, 1995; Bosch and Munoz, 2002).
More than 99% of squamous cell carcinomas harbour oncogenic
types of HPV, with HPV 16 being the most frequently encountered
(Walboomers et al, 1999). Partly in contrast, we and others have
found HPV DNA in 30–90% of cervical adenocarcinomas, with
HPV 18 as the predominant type (Tenti et al, 1996; Andersson
et al, 2003a,b; Clifford et al, 2003; Zielinski et al, 2004; Castellsague
et al, 2006).
Although tightly linked to cervical cancer development, HPV
infection alone is not sufficient for oncogenic transformation, and
other factors than HPV are required for the malignant transforma-
tion towards cervical adenocarcinomas (Skyldberg et al, 1999;
Pirog et al, 2000). The application of cytogenetic and molecular
cytogenetic techniques to study genomic alterations have identi-
fied frequent gains involving the long arm of chromosome 3 (Yang
et al, 2001). This observation is in concordance with previous
findings of recurrent 3q amplification in squamous cell carcinomas
(Heselmeyer et al, 1996, 1997a). The value of detection of genomic
amplification of 3q as a biomarker for progression during uterine
tumorigenesis was therefore evaluated in several studies. The
results showed that amplification of TERC is almost invariably
found in Pap smears assessed as HSIL (i.e., high squamous
intraepithelial lesions). In addition, a more recent study un-
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sambiguously established the central role of 3q for progression
from low-grade dysplastic lesions to higher grades and to invasive
carcinomas and showed that the gain of 3q can occur in
morphologically normal Pap smears of women who developed
cervical carcinomas after only a short latency (Heselmeyer-Haddad
et al, 2003, 2005). Gain of chromosomal region 3q is also
recurrently observed in other types of cancer, including tonsillar
cancer and carcinomas of the anogenital region that are both
associated with HPV DNA (Heselmeyer et al, 1997b; Dahlgren
et al, 2003; Stoltzfus et al, 2005).
In this study, we have determined TERC copy number gain in
cervical adenocarcinomas using interphase fluorescence in situ
hybridisation (FISH) on cytospins prepared from single-cell
suspensions of disintegrated archival paraffin-embedded tissue




The study includes formalin-fixed paraffin-embedded tumour
tissue specimens from 12 primary cervical adenocarcinomas
diagnosed and surgically treated at the Karolinska University
Hospital-Huddinge during 1992–2000 (Table 1). All tumour cases
were identified from the Swedish Central Cancer Registry
organised by the National Board of Health and Welfare. This
registry includes all cases of malignant tumours diagnosed
histopathologically after 1959, whereby each tumour is identified
by a topographical and histopathological code. All tumour samples
were collected with informed consent and approval from the local
ethics committee.
The clinical information for each case is detailed in Table 1 and
has been published previously (Andersson et al, 2003a). The
histopathological diagnosis was based on the WHO criteria. The 12
tumours were classified as cervical adenocarcinomas and all were
without any squamous cell component. Furthermore, the four
HPV-negative tumours (T4, T5, T8, T9) were histopathologically
re-evaluated and revealed typical morphology of cervical adeno-
carcinoma in agreement with the initial diagnosis. Immuno-
stainings with vimentin and carcinoembryonic antigen (CEA) were
carried out. Cases T4, T5 and T8 were strongly positive for CEA
and negative for vimentin, in agreement with the common pattern
for adenocarcinoma of cervical origin as reported by McCluggage
et al (2002). Case T9 showed atypical staining pattern (CEA was
negative and vimentin positive); however, the morphology was
strongly suggestive of cervical origin as judged by several
independent histopathologists. Seven tumours were well differen-
tiated (58%), one was moderately differentiated (8%) and
four tumours were poorly differentiated (33%). Clinical staging
was according to the International Federation of Gynecology
and Obstetrics (FIGO) classification for cervical cancer (Benedet
et al, 2000). At initial diagnosis, 10 tumours were classified as
stage I (83%) and two tumours as stage II (17%). Two
patients initially exhibited lymph node involvement (17%). All
patients were previously sampled for Pap smear analysis. All but one
Pap smear (which was evaluated as showing signs of cellular
inflammation) were assessed as normal at the time of the most
recent cytological evaluation (Table 1). Re-evaluation of the Pap
smears confirmed the initial diagnoses in all cases (Andersson et al,
2003a). All patients were retrospectively followed up from the time
of diagnosis until June 2005, and disease recurrence and survival
data recorded.
HPV status
Results from HPV screening analyses have been previously
published for all cases (Andersson et al, 2003a). Briefly, the
analyses were performed on extracted DNA obtained from sections
of paraffin blocks, of which the preceding section had been used
for morphological diagnosis. A fragment of 139–148bp was
amplified from the L1 region with GP5þ/GP6þ primers, HPV
typed by direct DNA sequencing and comparison to known HPV
sequence databases using the BLAST algorithm (www.ncbi.nlm.
nih.gov/BLAST). Eight of the 12 tumours were thus found to be
HPV-positive; five tumours were infected with HPV 18, two with
HPV 16 and one with HPV 45 (Table 1). In the remaining four
tumours, HPV was not detected.
Preparation of nuclei suspensions for FISH analysis
Single-layer nuclei preparations for interphase FISH hybridisations
were prepared using the Hedley method with modifications
(Castro et al, 1993). A 50-mm section was cut from each of the
12 formalin-fixed paraffin-embedded tumour tissue samples. After
deparaffinisation in xylene, the section was rehydrated in an
ethanol series and in distilled water, and the section was
disintegrated in 500ml of 0.1% protease/1 PBS (Protease:Type
XXIV, Bacterial, P 8038, Sigma, St Louis, MO, USA and Dulbecco’s
1 PBS, Life Technologies, Rockville, MD, USA) at 451C for
45–60min. The reaction was stopped by adding 500ml1 PBS at
room temperature. The sample was then filtered through a nylon
membrane (CN 051, DAKO, Glostrup, Denmark), centrifuged and





















1 1992 1990/normal 30 1B Poor No HPV 16 13 AwoD
2 1992 1989/normal 46 1B Poor No HPV 18 13 AwoD
3 1995 1992/normal 37 1B Well No HPV 18 10 AwoD
4 1997 1987/normal 39 1B Well No Not detected 8 AwoD
5 1992 1978/normal 50 2B Well Yes Not detected 13 AwoD
6 1994 1992/normal 32 1B Poor No HPV 18 11 AwoD
7 2000 1997/normal 62 1B Well No HPV 45 4 DoD
8 2000 1998/normal 64 1B Poor No Not detected 5 AwoD
9 1999 1996/normal 63 2B Moderate Yes Not detected 6 AwoD
10 2000 1999/inflammation 53 1A Well No HPV 16 5 AwoD
11 1997 1996/normal 45 1B Well No HPV 18 7 DoD
12 1993 1992/normal 49 1A Well No HPV 18 11 AwoD
AwoD¼alive without disease; DoD¼dead of disease; HPV¼human papillomavirus.
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sresuspended in 1 PBS. Cytospin slides were prepared using a
Shandon Cytospin
s centrifuge and fixed in an ethanol series.
FISH
Triple-colour FISH analysis was performed on each case using the
following probe set: a centromere-specific probe for chromosome
7 (CEP
s7); a centromere-specific probe for chromosome 3 (CEP3)
and a contig consisting of four overlapping BAC clones containing
the TERC gene at chromosomal location 3q26. All probes were
obtained from Vysis/Abbott Molecular Inc. (Des Plaines, IL, USA).
The details for this probe set, its sensitivity and specificity, as well as
experimental conditions were published previously (Heselmeyer-
Haddad et al, 2003). In short, CEP7 was labelled with Spectrum
Aquat (SA), CEP3 with Spectrum Greent (SG) and the TERC
contig with Spectrum Oranget (SO), using chemical labelling as
described (Bittner et al, 1996). Before hybridisation, the cytospin
slides were pretreated with a pepsin digestion and fixed in an
ethanol series. Slides were denatured in 70% formamide/2 SSC
for 3.5min at 801C. The probes were denatured according to the
manufacturer’s recommendations. After overnight hybridisation at
371C, the slides were first washed four times in 50% formamide/
2 SSC at 451C (once for 3min and three times for 7min),
followed by washes in 2 SSC at 451C for 5min and in 2 SSC/
0.1% NP40 at 451C for 5min. The slides were counterstained with
4,6-diamidino-2-phenylindole (DAPI), and subsequently em-
bedded in an antifade solution.
Scoring of FISH results
Fluorescence in situ hybridisation and image analyses were carried
out using a Leica DM-RXA fluorescence microscope (Leica,
Wetzlar, Germany) equipped with custom optical filters for DAPI,
SA, SG and SO (Chroma Technologies, Brattleboro, VT, USA) and
 40 Plan Apo (NA 1.25) objective. Images were taken in areas of
optimal cell density with minimal cellular clumps using an ORCA
ER (IEEE1394 I/F) digital camera (Hamamatsu, Bridgewater, NJ,
USA). Leica Q-Fluoro was used to acquire multifocus images for
each of the DAPI, SA, SG and SO optical filters. Ten to 16 images
were acquired and signal enumeration was performed on these
digital images for 208–641 nuclei for each case. The counted
signals were listed and evaluated in Excel-based customised
software.
Nuclei that could not be evaluated (e.g., because of insufficient
hybridisation or overlapping nuclei) were excluded from further
analysis. The results for all ‘countable’ nuclei were registered in
relocation charts in the form of patterns for the entire probe panel.
For example, the pattern (2-3-3) refers to two signals for CEP7,
three signals for CEP3 and three signals for TERC in a given
nucleus. Nuclei with normal signal numbers for the three probes
(i.e., 2-2-2) were recorded as ‘diploid’, and nuclei with four signals
for each probe (pattern 4-4-4) were considered ‘tetraploid’. The
background level for the CEP7–CEP3–TERC probe panel was
previously evaluated on cytological slides that contained nuclei
from normal cervical cells (Heselmeyer-Haddad et al, 2003). This
confirmed that deviation from the expected (2-2-2) pattern was
seen in less than 2% of normal cells.
RESULTS
Frequent gain of TERC in cervical adenocarcinomas
Twelve cervical adenocarcinomas (Table 1) were evaluated for
copy number changes of the TERC locus at chromosomal band
3q26 using interphase FISH. The three-colour probe panel
consisting of CEP7-CEP3-TERC was simultaneously hybridised to
cytospin slides with interphase nuclei prepared from formalin-
fixed tissue sections. All cases were successfully hybridised and
analysed, whereby 208–641 nuclei per case were scored. Figure 1
shows representative hybridisations. Both normal ‘diploid’ pat-
terns (2-2-2) and nuclei with nondiploid patterns were observed.
The results are summarised in Table 2. In all 12 tumours, a
significant proportion of ‘nondiploid’ nuclei was detected, and
nine of the tumours exhibited 450% ‘nondiploid’ nuclei. In the
individual tumours, nuclei with 42 TERC signals were found in
similar frequencies as cells with ‘nondiploid’ pattern, and almost
all nuclei with ‘nondiploid’ pattern exhibited 42 TERC signals. In
the ‘nondiploid’ nuclei, a ‘tetraploid’ pattern (4-4-4) was not
commonly observed. In 10 of the tumours, less than 1% of the
nuclei exhibited (4-4-4) and in two cases (4-4-4) was seen in 4 and
12%, respectively (Table 2; exemplified for case 3 in Figure 2).
Thus, gain of TERC was present in all tumours studied and was not
an effect of ‘tetraploid’ status.
Intratumour heterogeneity for gain and amplification of
the TERC locus
We observed different FISH patterns in the individual cases. For
several of the tumours, one or a few predominating patterns were
seen (exemplified for cases 1, 3 and 12 in Figure 2). In addition, all
cases exhibited varying proportions of different but recurrent
‘nondiploid’ patterns. Comparison of signal numbers recorded for
TERC vs CEP7 and CEP3 showed increased relative TERC copies in
the 12 cases studied (range 1.04–2.0; Table 2). The absolute mean
number of TERC signals per nuclei ranged between 2.3 (case 11)
and 5.2 (case 10), and in five of the tumours nuclei with more than
10 signals were repeatedly encountered (Table 2). Figure 1
illustrates nuclei of case 10 with amplifications of up to 20 TERC
signals and more, together with 5–6 signals for CEP3 and CEP7
(Figure 1G and H), which shows that TERC can be highly amplified
in certain cases. However, the more common pattern observed in
most cases are low-level copy numbers of TERC, often on a still
diploid background with patterns that can be reconciled with extra
chromosomes of 3 or an isochromosome 3q formation.
Gain of TERC and HPV infection
The clinical and follow-up information as well as HPV status of the
12 cervical adenocarcinomas are provided in Table 1. Eight cases
were HPV-positive and in the other four HPV was negative. Very
high proportions of ‘nondiploid’ nuclei with 42 TERC signals
were demonstrated in HPV-positive (83–99%) as well as HPV-
negative (86–99%) tumours. The absolute numbers of TERC
signals per nucleus were similarly increased in HPV-positive
(mean 3.4; range 2–22) and HPV-negative (mean 3.3; range 2–12)
tumours. No apparent associations between TERC copy numbers
and clinical characteristics, such as age at diagnosis, stage,
differentiation, lymph node involvement or outcome at follow-
up, were noted. Thus, gain of TERC is characteristic of cervical
adenocarcinomas per se.
DISCUSSION
In our study, we analysed a series of 12 primary cervical
adenocarcinomas for gain or amplification of the human
telomerase gene TERC, which maps to chromosome band 3q26.
Eight of the 12 carcinomas (67%) were HPV-positive (five tumours
were positive for HPV 18, two for HPV 16 and one for HPV 45)
(Skyldberg et al, 1999; Andersson et al, 2003a). We then used FISH
with a custom-designed probe panel that includes the human
telomerase gene (TERC) to assess the potential of this genetic
marker to ameliorate the morphological diagnosis of cervical
adenocarcinomas. This is the first study that reports the consistent
gain of the human telomerase gene TERC in cervical adenocarci-
nomas.
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sYang et al (2001) analysed 20 cases of cervical adenocarcinomas
with CGH and found that genetic alterations were evident in most
of the cervical adenocarcinomas, including the gain of 3q, which
was detected in 70% of these 20 tumours. From the findings
of similar 3q amplifications in adenocarcinomas as reported










Figure 1 Interphase FISH analysis showing gain of TERC in 3q26 in cervical adenocarcinomas. (A) Chromosomal location of the triple-colour probe set:
CEP 7 (labelled with Spectrum Aqua, which is pseudocoloured in yellowish-white in panels B, C, E and G), CEP 3 (Spectrum Green, pseudocoloured in
green in panels B, C, E and G), and TERC (Spectrum Orange, pseudocoloured in red). (B) Normal nuclei with the expected pattern of two signals per probe
per nucleus (2-2-2). (C and D) HPV-negative case number 4, (E and F) HPV-infected case number 6 and (G and H) HPV-positive case number 10. All
cases exhibit varying extents of gain of TERC. The cell clusters in C, E and G and in D, F and H show identical cells with either the triple-colour probe set
shown or with the TERC probe only, respectively.
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smechanisms are involved in the development of the two types of
cervical cancer (Yang et al, 2001). In our study, using FISH we
detected a gain of 3q in all our cases. This difference is likely
attributable to the different sensitivity of the respective techniques.
Detection of a trisomy by CGH requires this numerical aberration
to be present in at least 40% of the cells. Fluorescence in situ
hybridisation, of course, detects changes on a single-cell basis and
is therefore not sensitive to dilution. Additionally, small regional
low-copy number amplicons might escape detection by CGH.
In our study, HPV infection was not detected in four of the
cases, which could either reflect true HPV negativity or represent
‘false negatives’ owing to technical difficulties in HPV genome
detection. In the current literature, HPV infection has not been
reported in the same proportion in adenocarcinomas as in
squamous cervical carcinomas (Tenti et al, 1996; Skyldberg et al,
1999; Andersson et al, 2003b; Clifford et al, 2003; Zielinski et al,
2004; Castellsague et al, 2006). Perhaps, oncogenic factors other
than HPV are more likely to play a role in the malignant
transformation of cervical adenocarcinomas (Skyldberg et al, 1999;
Pirog et al, 2000).
The application of screening programmes has reduced the
incidence of squamous carcinoma in Sweden substantially during
the last decades (Ma ¨hlck et al, 1994; Ponten et al, 1995). Yet,
several studies suggest that a single Pap smear has a high false-
negative rate (Macgregor et al, 1994). A review of evidence-based
data revealed that as many as 50% of precancerous cervical lesions
may be missed by a single Pap test (Sherman et al, 1994). Kinney
et al (1998) showed that only 30% of women with histopatholo-
gically confirmed high-grade disease had corresponding atypia in
their Pap smears. Against this background, a new screening
strategy for cervical cancer has been presented in which HPV
testing is combined with cytological examinations (Walboomers
et al, 1999). However, screening methods currently utilised to
detect preinvasive and early invasive squamous cervical cancer had
only a limited effect in detecting precursor lesions of cervical
adenocarcinoma.
Hildesheim et al (1999) classified women as having rapid-onset
cervical cancer with the following criteria: a detection of cervical
cancer within 5 years of at least one normal Pap smear or within 10
years after the first sexual intercourse. Our data showing that 10 of
the 12 women had a normal Pap smear within 3 years before the
diagnosis of invasive disease may support the hypothesis of a
rapid-onset carcinoma. On the other hand, as the sensitivity of a
Pap smear for the detection of cervical adenocarcinomas is very
low (Krane et al, 2001), the rapid-onset hypothesis may not apply
to our cases.
Cervical squamous cell carcinomas are defined by a nonrandom
and recurrent distribution of genomic imbalances. In addition to
HPV, the sequential transformation of cervical squamous epithe-
lium requires the acquisition of additional copies of chromosome
arm 3q. In the current study, we wanted to analyse and understand
whether the gain of 3q plays a similar role in the tumorigenesis of
cervical adenocarcinomas. Using a genomic probe for the TERC
gene on chromosome band 3q26 in combination with two
centromere-specific probes (CEP3 and CEP7), we showed high
copy numbers of this locus in cervical adenocarcinomas. Gain or
amplification of 3q was found in all cervical adenocarcinomas
investigated. Therefore, the application of this probe set may
provide an objective genetic test for the diagnosis of cervical
adenocarcinomas and might assist in the interpretation of smears
with a high degree of glandular cells.
Heselmeyer-Haddad et al (2003) showed in a series of Pap
smears of cervical precursor lesions of squamous cell origin that
analysis of the TERC gene amplification is able to distinguish
normal epithelium and low-grade dysplasia from the group of
high-grade lesions with high specificity and sensitivity. In another
paper, the same group showed that gain of TERC was found in 33%
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scarcinoma in situ or invasive cervical squamous cancer in the
future (Heselmeyer-Haddad et al, 2005). In the same paper, the
authors were also able to show that all CIN1/CIN2 lesions with a
diploid pattern for the TERC probe panel (CEP7–CEP3–TERC)
eventually regressed to normal Pap smears, whereas the CIN1/
CIN2 lesions with TERC amplification progressed. Lesions with a
tetraploid pattern for the panel (four signals for each probe) could
develop either way. The author concluded that the detection of
gain and amplification of TERC in routinely collected Pap smears
can assist in identifying lesions with a high progression risk. As the
results of the current study indicate, TERC appears to play a
similar important role in the carcinogenesis of cervical adeno-
carcinomas. Interestingly, even the patterns of gain found in the
adenocarcinomas are very comparable to the patterns found in
cervical dysplasias of squamous cell type (Heselmeyer-Haddad
et al, 2003, 2005). The most common patterns observed for both of
the cell types are low-level gains of TERC on a diploid background
(3–5 signals of TERC). Given the similarity to the results of the
studies of TERC in cervical squamous cell lesions, it seems to be a
distinct possibility that analysis of TERC gain may also help to find
women at risk for developing adenocarcinoma. An objective
molecular marker in this patient group is of extreme importance
because of the cytomorphologically difficult identification of these
cells and the limited numbers of representative cells owing to
technical problems in sampling these lesions. As shown in our
study, many women with cervical adenocarcinoma presented with
morphologically normal Pap smears, often only 1–2 years before
diagnosis. A marker like TERC could have considerable impact on
the detection of cervical adenocarcinomas at an earlier stage.
Fluorescence in situ hybridisation analyses of precursor lesions,
that is, adenocarcinomas in situ and dysplasias will be the next
step to verify the potential of TERC as a marker of early detection
and progression in cervical adenocarcinomas. We are therefore
planning to conduct both retrospective studies with archival Pap









































































































































































































































































































Figure 2 Diagrams illustrating the scoring results from interphase FISH analyses in cases 1, 3 and 12. Scoring patterns for CEP3–CEP7–TERC are given
along the x axis and the numbers of detected nuclei with a given pattern are given on the y axis.
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